Lyell Immunopharma, Inc. (LYEL) intrinsic value & 10-year financials
Lyell Immunopharma, Inc. (LYEL) has a Graham intrinsic value of $945.51 per share. At $8.12 on Oct 17, 2026, the stock trades 99% below that value. Over the last 8 fiscal years revenue shrank 38.4% a year to $36.0K, with an average return on invested capital of -14.4%.
- Graham intrinsic value
- $945.51
- Share price (Oct 17, 2026)
- $8.12
- Price vs Graham value
- 99% below
- Market cap
- $138.8M
- Revenue (FY2025)
- $36.0K
- Revenue growth (8-yr CAGR)
- -38.4%
- ROIC (10-yr avg)
- -14.4%
- Free cash flow (FY2025)
- -$150.8M
LYEL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $36.0K | -$274.4M | -$16.06 | -$150.8M | -748344.4% | -96.5% |
| FY2024 | $61.0K | -$343.0M | -$1.31 | -$162.9M | -588123.0% | -76.7% |
| FY2023 | $130.0K | -$234.6M | -$0.93 | -$166.4M | -190006.2% | -35.0% |
| FY2022 | $84.7M | -$183.1M | -$0.74 | -$193.8M | -220.9% | -24.8% |
| FY2021 | $10.7M | -$250.2M | -$0.00 | -$191.8M | -2016.7% | -156.1% |
| FY2020 | $7.8M | -$204.5M | -$0.00 | -$212.4M | -2732.6% | 53.5% |
| FY2019 | $657.0K | -$129.4M | -$0.00 | $23.4M | -15538.7% | 234.7% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Lyell Immunopharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Lyell Immunopharma, Inc. has historically struggled to out-earn its cost of capital, averaging just -25.5% ROIC.
Lyell Immunopharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Lyell Immunopharma, Inc. is modeled at -38.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $945.51 per share.